Navigation Links
Proteolix to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting
Date:10/17/2009

linical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About PR-957

PR-957 is the first highly selective, small molecule inhibitor of the immunoproteasome. The immunoproteasome is a specific form of the proteasome found in many cells of the immune system. PR-957 selectively targets a subunit of the immunoproteasome, known as LMP7 (B5i) and halts the production of cytokines associated with autoimmune inflammation. In preclinical studies, PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to eliminate visible signs of disease at the highest dose.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.

SOURCE Proteolix, Inc.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
5. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
8. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
9. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,5...participatinginaschemetodefraudtheExport-ImportBan...nnouncedAssistantAttorneyGeneraloftheCriminalDivis...GratacosoftheEx-ImBank,OfficeoftheInspectorGeneral...bertsinU.S.DistrictCourtinWashingtontoaone-countcr...
(Date:11/23/2009)....23/PRNewswire/--TwooftheChicagoarea,sleadingBoard...rainwomen,sbreastimaging,couplingthelatesttechnolo...rasoundwiththeabilitytohavethefullrangeofdigitalim...beforesheleavestheoffice.Drs.AhmedFaragandJoanWerb...tthecurrent6-9monthwaitforanappointmentcommonlyfou...
(Date:11/23/2009)...alif.,Nov.23/PRNewswire-FirstCall/--AccurayIncorpo...osurgery,announcedtodaythatitsmanagementisschedule...ferenceinNewYorkonTuesday,December1,2009at9:00a.m....rganSmall/MidCapConferenceinNewYorkonThursday,Dece...castofeachpresentationwillbeavailableonlinefromthe...
Breaking Medicine Technology:Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference 2Acupuncture may bring relief for a common condition in women 54970 1Acupuncture may bring relief for a common condition in women 54970 2Switching on the power of stem cells 9639 1Switching on the power of stem cells 9639 2Princeton team learns why some drugs pack such a punch 9635 1Princeton team learns why some drugs pack such a punch 9635 2Princeton team learns why some drugs pack such a punch 9635 3
....m. today, Thursday, August 16, 2007, MALVERN, Pa...: AUXL ) today announced that the Company has,rec...stration ("FDA") to,resume its phase III clinical ...jection), formerly referred to as AA4500, in the t...ill hold a conference call today,August 16, at 10:...
...on on Track -, BRISBANE, Australia, Aug. 16 Prog...) today announced it has,executed an agreement wit...,Organisation, to utilise their services for a num...s agreement includes the execution of the,Phase 3 ...reatment of,primary liver cancer (hepatocellular c...
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3
(Date:11/23/2009)...,, AmericanCollegeofMedicalGenetics(ACMG)Enc...iononNationalFamilyHistoryDay,Thanksgiving2009 ,...isThanksgivingisthesixthannualNationalFamilyHistor...CollegeofMedicalGenetics(ACMG)encourageseveryoneto...dygatheredthispotentiallylife-savinginformation,to...
(Date:11/23/2009)...More open on-the-job interaction might ease the pr...23 (HealthDay News) -- Men who bottle up their ang...their hearts, a new Swedish study indicates. , ...tment over conflicts with a fellow worker or super...rt attack or die of heart disease as those who ven...
(Date:11/23/2009)...,, ActingSecretaryEncouragesUseofPAPreferredP...PRNewswire-USNewswire/--Toensurethatyourfamilyhasa...etaryRussellReddingisurgingresidentstofollowafewba...ftovers. ,, "Followingandunderstandingproperfoo...makingsureyourThanksgivingdinnerissafetoeat,"saidR...
(Date:11/23/2009)...,, HATBORO,Pa.,Nov.23/PRNewswire-FirstCall/--...oviderofenterprisemobilitysolutionsforthehealthcar...formerVicePresidentofManagedServicesatSiemensHealt...egicHealthcareServices. ,, (Logo: http://www.ne..., AsVicePresidentofStrategicHealthcareServicesforI...
(Date:11/23/2009)...,, ClinicsContinuetoTargetIndividualsintheRec... /PRNewswire-USNewswire/--TheDepartmentofHealthan...inationclinicsatlocalStateHealthCentersinDelaware,...nesday,Nov.25.TheH1N1vaccinewillbeadministeredforf...venothadpreviousaccesstothevaccine.Thedepartmentas...
Breaking Medicine News(10 mins):Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Pennsylvania Agriculture Department Encourages Proper Food Handling, Offers Safety Tips for Thanksgiving 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2
...discovery reveals a new cause of thyroid cancer. R...tumors, one of three genetic changes // happen. T...atients have not been exposed to radiation, the ch...e gene changes or mutations transform normal cells...
...ing to the Centers for Disease Control and Prevent...living with HIV.// Human Immuno Deficiency Virus ... Previous research has shown circumcised men ar...ey found each sample contained cells expressing th...
...nk between migraines and the risk of coronary hear...t study shows // no link between the two but does ...est pain, also known as angina. People with a h...port a history of chest pain than those without a ...
...chers now say they’ve found one drug that may succ...cancer.// For the study 22 patients with breast, p...r were involved , 42 percent had their tumors eith... so there’s much less side effects because it targ...
...study finds Alzheimer’s patients lose the ability ...sease progresses. // Researchers conducted a st... skills and Alzheimer’s disease. The study include... The study also included 23 healthy elderly people...
...chers say their discovery of a new compound known ...conjunction with // chemotherapy drugs such as cis...over 48 hours, small amounts of SP-4-84 made campt... caused by chemotherapeutic drugs. However, this w...
Other Medicine News:
Buffered Wright-Giemsa Stain
Giemsa Stain
Albumin (BCP)
Albumin Reagent Set
Medicine Products: